JP2009019052A - 経口投与用製剤 - Google Patents
経口投与用製剤 Download PDFInfo
- Publication number
- JP2009019052A JP2009019052A JP2008223685A JP2008223685A JP2009019052A JP 2009019052 A JP2009019052 A JP 2009019052A JP 2008223685 A JP2008223685 A JP 2008223685A JP 2008223685 A JP2008223685 A JP 2008223685A JP 2009019052 A JP2009019052 A JP 2009019052A
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- pharmaceutical preparation
- oral administration
- lysozyme chloride
- ibuprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 16
- 102000016943 Muramidase Human genes 0.000 claims abstract description 16
- 108010014251 Muramidase Proteins 0.000 claims abstract description 16
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 16
- 229960002335 bromhexine hydrochloride Drugs 0.000 claims abstract description 16
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960000274 lysozyme Drugs 0.000 claims abstract description 16
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 16
- 239000004325 lysozyme Substances 0.000 claims abstract description 16
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims abstract description 11
- 229960005489 paracetamol Drugs 0.000 claims abstract description 11
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000001387 anti-histamine Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 10
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 abstract description 8
- 229960004708 noscapine Drugs 0.000 abstract description 8
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 abstract description 7
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 abstract description 5
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 4
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229920003114 HPC-L Polymers 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 229940124579 cold medicine Drugs 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- UCDKONUHZNTQPY-UHFFFAOYSA-N bromhexine hydrochloride Chemical compound Cl.C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N UCDKONUHZNTQPY-UHFFFAOYSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】(a)イブプロフェン、(b)抗ヒスタミン薬、(c)塩酸ブロムヘキシン、塩酸アンブロキソール及び塩化リゾチームからなる群より選ばれる1種または2種以上の薬物並びに(d)アセトアミノフェンを配合した経口投与用製剤。
【選択図】なし
Description
比較例1
成分 配合量(g)
塩酸ブロムヘキシン 12
ポリエチレングリコール6000 20
マンニトール 200
HPC−L 15
セイセイスイ 適量
上記処方に基づき、撹拌造粒法で散剤を製した。
比較例1の処方にアセトアミノフェン900gを追加し、撹拌造粒法で散剤を製した。
成分 配合量(g)
イブプロフェン 300
塩酸ブロムヘキシン 12
塩化リゾチーム 60
ノスカピン 48
マンニトール 500
アビセルPH−101 400
HPC−L 50
セイセイスイ 適量
上記処方に基づき、撹拌造粒法により散剤を製した。
比較例2の処方にアセトアミノフェン300gを追加し、撹拌造粒法で散剤を製した。
成分 配合量(g)
イブプロフェン 150
塩酸ブロムヘキシン 12
塩化リゾチーム 60
d−マレイン酸クロルフェニラミン 3.5
マンニトール 500
アビセルPH−101 400
HPC−L 50
セイセイスイ 適量
上記処方に基づき、撹拌造粒法により散剤を製した。
比較例3の処方にアセトアミノフェン600gを追加し、撹拌造粒法で散剤を製した。
成分 配合量(g)
イブプロフェン 300
塩酸ブロムヘキシン 12
塩化リゾチーム 60
d−マレイン酸クロルフェニラミン 3.5
ノスカピン 48
ポリエチレングリコール6000 50
マンニトール 500
アビセルPH−101 400
HPC−L 50
セイセイスイ 適量
上記処方に基づき、撹拌造粒法により散剤を製した。
比較例4の処方にアセトアミノフェン300gを追加し、撹拌造粒法で散剤を製した。
比較例1〜4及び実施例1〜4で製造した製剤をそれぞれ1gを全てビンに充填、密栓し,50℃−1週間,40℃−3週間での塩酸ブロムヘキシン,塩化リゾチームの安定性を評価した(表1〜4)。なお、塩酸ブロムヘキシンはHPLC法により、塩化リゾチームは濁度法によりそれぞれ定量した。数値は全て対直後%である。
Claims (1)
- (a)イブプロフェン、(b)抗ヒスタミン薬、(c)塩酸ブロムヘキシン、塩酸アンブロキソール及び塩化リゾチームからなる群より選ばれる1種または2種以上の薬物並びに(d)アセトアミノフェンを配合した経口投与用製剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008223685A JP4983750B2 (ja) | 1997-01-17 | 2008-09-01 | 経口投与用製剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1997006216 | 1997-01-17 | ||
JP621697 | 1997-01-17 | ||
JP2008223685A JP4983750B2 (ja) | 1997-01-17 | 2008-09-01 | 経口投与用製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10001979A Division JPH10259130A (ja) | 1997-01-17 | 1998-01-08 | 経口投与用製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009019052A true JP2009019052A (ja) | 2009-01-29 |
JP4983750B2 JP4983750B2 (ja) | 2012-07-25 |
Family
ID=40358992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008223685A Expired - Fee Related JP4983750B2 (ja) | 1997-01-17 | 2008-09-01 | 経口投与用製剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4983750B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4093B1 (ro) * | 2004-05-03 | 2011-02-28 | Boehringer Ingelheim International Gmbh | Utilizare a compoziţiei farmaceutice topice cu conţinut de ambroxol |
JP2017222677A (ja) * | 2010-07-30 | 2017-12-21 | 興和株式会社 | ロキソプロフェン含有医薬製剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06239744A (ja) * | 1993-02-18 | 1994-08-30 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH07188004A (ja) * | 1993-12-28 | 1995-07-25 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH07188019A (ja) * | 1993-12-28 | 1995-07-25 | Taisho Pharmaceut Co Ltd | 鎮咳去痰組成物 |
JPH0826996A (ja) * | 1994-07-15 | 1996-01-30 | Taisho Pharmaceut Co Ltd | コデイン含有カプセル剤 |
JPH08333246A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
JPH08333265A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
-
2008
- 2008-09-01 JP JP2008223685A patent/JP4983750B2/ja not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06239744A (ja) * | 1993-02-18 | 1994-08-30 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH07188004A (ja) * | 1993-12-28 | 1995-07-25 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH07188019A (ja) * | 1993-12-28 | 1995-07-25 | Taisho Pharmaceut Co Ltd | 鎮咳去痰組成物 |
JPH0826996A (ja) * | 1994-07-15 | 1996-01-30 | Taisho Pharmaceut Co Ltd | コデイン含有カプセル剤 |
JPH08333246A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
JPH08333265A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4093B1 (ro) * | 2004-05-03 | 2011-02-28 | Boehringer Ingelheim International Gmbh | Utilizare a compoziţiei farmaceutice topice cu conţinut de ambroxol |
JP2017222677A (ja) * | 2010-07-30 | 2017-12-21 | 興和株式会社 | ロキソプロフェン含有医薬製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP4983750B2 (ja) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2397262T3 (es) | Composiciones líquidas de absorción rápida que contienen una amina y un AINE | |
US5641512A (en) | Soft gelatin capsule compositions | |
KR101695580B1 (ko) | 증가된 안정성의 신규한 액체 조성물 | |
EP0312340A1 (en) | Use of carbomer in controlled-release formulations to enhance or increase the dissolution rate of poorly soluble pharmacologically active substances | |
JPH107552A (ja) | 持続放出性製剤 | |
JP2007091633A (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
CZ210496A3 (en) | Method improving solution process of difficult-to dissolve pharmaceutically active compounds | |
EP0839029A1 (en) | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules | |
JP4853818B2 (ja) | イブプロフェン及び塩酸アンブロキソール含有固形製剤 | |
JP2849047B2 (ja) | ジクロフェナクナトリウム持続性製剤およびその製法 | |
JP4983750B2 (ja) | 経口投与用製剤 | |
JPH0383922A (ja) | イブプロフェン含有経口投与用組成物 | |
JP2005514367A (ja) | アセトアミノフェン組成物 | |
JP6179515B2 (ja) | 安定化された内服用固形製剤 | |
JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
JP2005187328A (ja) | イブプロフェン含有解熱鎮痛組成物、及び感冒薬 | |
JPH10259130A (ja) | 経口投与用製剤 | |
JPH10101581A (ja) | 塩酸ブロムヘキシンの安定化製剤及び安定化方法 | |
JP2011046666A (ja) | 医薬組成物 | |
JP2017171626A (ja) | プロピオン酸系非ステロイド性消炎鎮痛薬を含有した医薬組成物 | |
JP4899304B2 (ja) | 塩酸アンブロキソール含有内服用固形製剤 | |
JP2018100259A (ja) | 固形製剤 | |
TWI252755B (en) | Medical composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid | |
JP2004059579A (ja) | 鎮痛剤組成物 | |
RU2182824C1 (ru) | Фармацевтический состав с противовоспалительным, анальгетическим и жаропонижающим действием |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090609 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120409 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |